연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3655. MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer
Cheng Hyun Lee1†, Soo Young Park1,2,3,4†, Jae Seok Lee5†, Da Sol Kim1, Ha Yeon Kim1, Min Ji Song1,
Seock‑Ah Im6,7,8, Kyung‑Hun Lee6,7,8, Dae‑Won Lee6,7,8, Ilias P. Nikas9, Ji Won Koh1,2, So Hyeon Yang1,2,
Hyebin Lee4,10* and Han Suk Ryu
Breast Cancer Res. 2025 Jul 22;27(1):136.
Link
3654. Improving HER2 Diagnostics with Digital Real-Time PCR for
Ultrafast, Precise Prediction of Anti-HER2 Therapy
Response in Patients with Breast Cancer
Hee-Joo Choi, Soo Young Park, Minsik Song, Jinhyuk Chang, YoonSik Kim, Hosub Park,
Chihwan David Cha, Sohyeon Yang, Nam Hun Heo, Min Ji Song, Da Sol Kim,
Hayeon Kim, Minuk Kim, Jae Eun Park, Yesung Lee, EunChae Ji, Heekyoung Chung,
Ilecheon Jeong, Mineui Hong, Jin-Wu Nam, Mee-Hye Oh, Ji-Hye Lee, Jinwoo Seol,
Hee-Young Won, Hyun-Woo Song, Jaewon Eom, Do Young Lee,* Han Suk Ryu,*
Si-Hyong Jang,* and Jeong-Yeon Lee
Small Methods. 2025 Sep 6:e00599.
Link
3653. Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression.
Kim JM, Nam AR, Oh KS, Bang JH, Jeong Y, Choo SY, Kim HJ, Lee SI, Yoon J, Kim TY, Oh DY.
Cell Commun Signal.
2025 Dec 17;23(1):530.
Link
3652. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris HA, Bouattour M, Tanasanvimon S, Zaucha R, Avallone A, Cundom J, Kuzko A, Wang J, Xynos I, Vogel A, Valle JW.
J Hepatol. 2025 Nov;83(5):1092-1101.
Link
3651. An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer.
Yoon J, Oh DY.
Expert Opin Biol Ther. 2025 Sep;25(9):935-946.
Link
3650. YAP as a therapeutic target to reverse trastuzumab resistance.
Nam AR, Oh KS, Bang JH, Jeong Y, Choo SY, Kim HJ, Lee SI, Kim JM, Yoon J, Kim TY, Oh DY.
Gastric Cancer. 2025 Sep;28(5):799-813.
Link
3649. JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction.
Oh KS, Nam AR, Bang JH, Jeong Y, Choo SY, Kim HJ, Lee SI, Kim JM, Yoon J, Kim TY, Oh DY.
Int J Biol Sci. 2025 Aug 22;21(12):5460-5475.
Link
3648. Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma.
Lee SI, Nam AR, Oh KS, Kim JM, Bang JH, Jeong Y, Choo SY, Kim HJ, Yoon J, Kim TY, Oh DY.
Cell Commun Signal. 2025 Jun 13;23(1):281.
Link
3647. Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
Oh DY, Ikeda M, Lee CK, Rojas C, Hsu CH, Kim JW, Shen L, Furuse J, Park JO, Borad M, de Braud F, Bridgewater J, Lee SS, Moehler M, Audhuy F, Osada M, Sato M, Yoo C.
Hepatology. 2025 Mar 1;81(3):823-836.
Link
3646. Delayed Separation of Kaplan-Meier Curves is Commonly Observed in Studies of Advanced/Metastatic Solid Tumors Treated with Anti-PD-(L)1 Therapy: Systematic Review and Meta-Analysis.
Oh DY, Rokutanda N, Żotkiewicz M, He P, Stocks J, Johnson ML.
Target Oncol. 2025 Jan;20(1):45-56.
Link